Table 2 Summary of tumour response and median time to progression
BRAF inhibitor followed by ipilimumab (n = 28) | Ipilimumab followed by a BRAF inhibitor (n = 6) | |||||
|---|---|---|---|---|---|---|
Vemurafenib | Dabrafenib | Ipilimumab | Ipilimumab | Vemurafenib | Dabrafenib | |
Patients, n | 12 | 16 | 28 | 6 | 4 | 2 |
Objective tumour response*, n (%) | 4 (33) | 10 (63) | 7 (25) | 1 (17) | 3 (75) | 2 (100) |
CR | 0 (0) | 1 (6) | 0 (0) | 0 (0) | 0 (0) | 0 (0) |
PR | 4 (33) | 9 (56) | 7 (25) | 1 (17) | 3 (75) | 2 (100) |
SD | 4 (33) | 1(6) | 7 (25) | 2 (33) | 1 (25) | 0 (0) |
PD | 4 (33) | 5 (31) | 7 (25) | 3 (50) | 0 (0) | 0 (0) |
Median time to progression, months (95 % CI) | 3.6 (3.3–3.8) | 4.0 (2.1–5.9) | 3.4 (2.8–4.1) | |||